BACKGROUND: Prior claims analyses suggest that the use of intravenous inotropic therapy for patients hospitalized with heart failure varies substantially by hospital. Whether differences in the clinical characteristics of the patients explain observed differences in the use of inotropic therapy is not known. METHODS AND RESULTS: We sought to characterize institutional variation in inotrope use among patients hospitalized with heart failure before and after accounting for clinical factors of patients. Hierarchical generalized linear regression models estimated risk-standardized hospital-level rates of inotrope use within 209 hospitals participating in Get With The Guidelines-Heart Failure (GWTG-HF) registry between 2005 and 2011. The association between risk-standardized rates of inotrope use and clinical outcomes was determined. Overall, an inotropic agent was administered in 7691 of 126 564 (6.1%) heart failure hospitalizations: dobutamine 43%, dopamine 24%, milrinone 17%, or a combination 16%. Patterns of inotrope use were stable during the 7-year study period. Use of inotropes varied significantly between hospitals even after accounting for patient and hospital characteristics (median risk-standardized hospital rate, 5.9%; interquartile range, 3.7%-8.6%; range, 1.3%-32.9%). After adjusting for case-mix and hospital structural differences, model intraclass correlation indicated that 21% of the observed variation in inotrope use was potentially attributable to random hospital effects (ie, institutional preferences). Hospitals with higher risk-standardized inotrope use had modestly longer risk-standardized length of stay (P=0.005) but had no difference in risk-standardized inpatient mortality (P=0.12). CONCLUSIONS: Use of intravenous inotropic agents during hospitalization for heart failure varies significantly among US hospitals even after accounting for patient and hospital factors.
RCT Entities:
BACKGROUND: Prior claims analyses suggest that the use of intravenous inotropic therapy for patients hospitalized with heart failure varies substantially by hospital. Whether differences in the clinical characteristics of the patients explain observed differences in the use of inotropic therapy is not known. METHODS AND RESULTS: We sought to characterize institutional variation in inotrope use among patients hospitalized with heart failure before and after accounting for clinical factors of patients. Hierarchical generalized linear regression models estimated risk-standardized hospital-level rates of inotrope use within 209 hospitals participating in Get With The Guidelines-Heart Failure (GWTG-HF) registry between 2005 and 2011. The association between risk-standardized rates of inotrope use and clinical outcomes was determined. Overall, an inotropic agent was administered in 7691 of 126 564 (6.1%) heart failure hospitalizations: dobutamine 43%, dopamine 24%, milrinone 17%, or a combination 16%. Patterns of inotrope use were stable during the 7-year study period. Use of inotropes varied significantly between hospitals even after accounting for patient and hospital characteristics (median risk-standardized hospital rate, 5.9%; interquartile range, 3.7%-8.6%; range, 1.3%-32.9%). After adjusting for case-mix and hospital structural differences, model intraclass correlation indicated that 21% of the observed variation in inotrope use was potentially attributable to random hospital effects (ie, institutional preferences). Hospitals with higher risk-standardized inotrope use had modestly longer risk-standardized length of stay (P=0.005) but had no difference in risk-standardized inpatient mortality (P=0.12). CONCLUSIONS: Use of intravenous inotropic agents during hospitalization for heart failure varies significantly among US hospitals even after accounting for patient and hospital factors.
Entities:
Keywords:
cardiotonic agents; heart failure; outcome and process assessment (health care); physician’s practice patterns
Authors: Uri Elkayam; Gudaye Tasissa; Cynthia Binanay; Lynne W Stevenson; Mihai Gheorghiade; J Wayne Warnica; James B Young; Barry K Rayburn; Joseph G Rogers; Teresa DeMarco; Carl V Leier Journal: Am Heart J Date: 2007-01 Impact factor: 4.749
Authors: Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade Journal: JAMA Date: 2002-03-27 Impact factor: 56.272
Authors: John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher Journal: Eur Heart J Date: 2012-05-19 Impact factor: 29.983
Authors: Daniel De Backer; Patrick Biston; Jacques Devriendt; Christian Madl; Didier Chochrad; Cesar Aldecoa; Alexandre Brasseur; Pierre Defrance; Philippe Gottignies; Jean-Louis Vincent Journal: N Engl J Med Date: 2010-03-04 Impact factor: 91.245
Authors: Elizabeth S DeWitt; Katherine J Black; Ravi R Thiagarajan; James A DiNardo; Steven D Colan; Francis X McGowan; John N Kheir Journal: J Appl Physiol (1985) Date: 2016-05-05
Authors: David Snipelisky; Marat Fudim; Antonio Perez; Matthew Nayor; Natasha M Lever; David S Raymer; Andrew N Rosenbaum; Omar AbouEzzeddine; Adrian F Hernandez; Lynne Warner Stevenson; Lauren G Gilstrap Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2020-08-19
Authors: Tiana Nizamic; M Hassan Murad; Larry A Allen; Colleen K McIlvennan; Sara E Wordingham; Daniel D Matlock; Shannon M Dunlay Journal: JACC Heart Fail Date: 2018-07-11 Impact factor: 12.035
Authors: Nancy Luo; Steven J Lippmann; Robert J Mentz; Melissa A Greiner; Bradley G Hammill; N Chantelle Hardy; Warren K Laskey; Paul A Heidenreich; Chun-Lan Chang; Adrian F Hernandez; Lesley H Curtis; Pamela N Peterson; Gregg C Fonarow; Emily C O'Brien Journal: J Am Heart Assoc Date: 2019-02-05 Impact factor: 5.501
Authors: Tuukka Tarvasmäki; Johan Lassus; Marjut Varpula; Alessandro Sionis; Reijo Sund; Lars Køber; Jindrich Spinar; John Parissis; Marek Banaszewski; Jose Silva Cardoso; Valentina Carubelli; Salvatore Di Somma; Alexandre Mebazaa; Veli-Pekka Harjola Journal: Crit Care Date: 2016-07-04 Impact factor: 9.097